Page 203 - EJMO-9-3

Eurasian Journal of
Medicine and Oncology Medication therapy based on HbA1c

Ethics approval and consent to participate sodium-glucose cotransporter 2 (SGLT2) inhibitors in
patients with acute heart failure: A systematic review and
The study was approved by the Ethics Board of the meta-analysis. Front Cardiovasc Med. 2024;11:1388337.
Republican Specialized Scientific-Practical Medical
Center of Cardiology in Uzbekistan (Approval ID: doi: 10.3389/fcvm.2024.1388337
ПЗ-202007041). Participants provided written consent to 9. Naha S, Gardner MJ, Khangura D, Kurukulasuriya LR,
participate in the study. Sowers JR. Hypertension in Diabetes. In: Feingold KR,
Ahmed SF, Anawalt B, et al., editors. Endotext. MDText.com
Consent for publication Inc.; 2000. Available from: https://www.ncbi.nlm.nih.gov/
books/nbk279027 [Last accessed on 2024 Aug 07].
The participants provided written consent to use and
publish the data and results. 10. Alpert CM, Smith MA, Hummel SL, Hummel EK. Symptom
burden in heart failure: Assessment, impact on outcomes,
Availability of data and management. Heart Fail Rev. 2017;22(1):25-39.
Data can be obtained by request from the corresponding doi: 10.1007/s10741-016-9581-4
author. 11. Diabetes control and complications trial (DCCT): Results of
feasibility study. The DCCT research group. Diabetes Care.
References 1987;10(1):1-19.

1. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes doi: 10.2337/diacare.10.1.1
atlas: Global estimates of the prevalence of diabetes for 2011 12. Gale EA, Gillespie KM. Diabetes and gender. Diabetologia.
and 2030. Diabetes Res Clin Pract. 2011;94(3):311-321. 2001;44(1):3-15.
doi: 10.1016/j.diabres.2011.10.029 doi: 10.1007/s001250051573
2. Effect of intensive blood-glucose control with metformin on 13. Chou CL, Zheng CM, Chiu HW, et al. Impact of acute
complications in overweight patients with type 2 diabetes kidney injury, co-existing with and without chronic kidney
(UKPDS 34). UK prospective diabetes study (UKPDS) disease on the short-term adverse outcomes following
Group. Lancet. 1998;352(9131):854-865. atherosclerotic cardiovascular disease events in patients
3. American Diabetes Association. Glycemic goals and with diabetes. J Multidiscip Healthc. 2025;18:2019-2037.
hypoglycemia: Standards of care in diabetes - 2025. Diabetes doi: 10.2147/JMDH.S123456
Care. 2025;48(Suppl 1):S128-S145.
14. Vloemans AF, Eilander MM, Rotteveel J, et al. Youth with
doi: 10.2337/dc25-S006 type 1 diabetes taking responsibility for self-management:
4. Wang JS, Liu WJ, Lee CL. HbA1c trajectory and The importance of executive functioning in achieving
cardiovascular outcomes: An analysis of data from the glycemic control: Results from the longitudinal DINO study.
action to control cardiovascular risk in diabetes (ACCORD) Diabetes Care. 2019;42(2):225-231.
study. Ther Adv Chronic Dis. 2021;12:20406223211026391.
doi: 10.2337/dc18-1143
doi: 10.1177/20406223211026391 15. Tucker B, Ong KL, Robledo K, Keech A, Patel S. Association
5. Nauck MA, Meier JJ. The incretin effect in healthy individuals of inflammation, triglycerides and lipoprotein(a) with
and those with type 2 diabetes: Physiology, pathophysiology, cardiovascular events in the UK Biobank. Eur Heart J.
and response to therapeutic interventions. Lancet Diabetes 2024;45(Suppl 1):ehae666.2751.
Endocrinol. 2016;4(6):525-536.
doi: 10.1093/eurheartj/ehae666.2751
doi: 10.1016/S2213-8587(15)00482-9
16. Quispe R, Sweeney T, Varma B, Agarwala A, Michos ED.
6. Joseph JJ, Deedwania P, Acharya T, et al. Comprehensive Recent updates in hypertriglyceridemia management
management of cardiovascular risk factors for adults with for cardiovascular risk reduction. Curr Atheroscler
type 2 diabetes: A scientific statement from the American Rep. 2022;24:52-64.
heart association. Circulation. 2022;145(9):e722-e759. doi: 10.1007/s11883-022-01052-4
doi: 10.1161/CIR.0000000000001040
17. Wu K, Chen J, Lin Y, Wang J. A cohort study on the
7. Johnson L, Wang H. Cardioprotective effects of GLP-1 correlation between serum Klotho levels and all-cause
receptor agonists and SGLT2 inhibitors in T2DM patients. mortality in American diabetic populations. Diabetol Metab
J Diabetes Complications. 2024;38(3):145-158. Syndr. 2025;17:124.
doi: 10.1016/j.jdiacomp.2024.01.005 doi: 10.1186/s13098-025-01686-9
8. Hou J, Ren L, Hou Q, et al. Efficacy and safety of 18. Xie R, Seum T, Sha S, et al. Improving 10-year cardiovascular

Volume 9 Issue 3 (2025) 195 doi: 10.36922/EJMO025160133